DSIP vs Pinealon

DSIP

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, first isolated from rabbit cerebral venous blood during induced sleep by Schoenenberger and Monnier in 1977. DSIP modulates sleep architecture by promoting delta wave (slow-wave) sleep patterns through interactions with multiple neurotransmitter systems, including GABAergic, glutamatergic, and opioidergic pathways. It also influences hypothalamic-pituitary axis regulation, affecting cortisol and growth hormone secretion patterns. Studies published in Peptides demonstrated that DSIP use normalized disturbed sleep patterns in animal models of chronic stress without producing the sedation or rebound effects associated with classical hypnotic agents. Research by Graf and Kastin (1986) in Neuroscience & Biobehavioral Reviews characterized DSIP's ability to cross the blood-brain barrier and its unusually long biological half-life relative to other neuropeptides. Additional investigations have indicated stress-protective effects, with DSIP reducing corticotropin levels and modulating the hypothalamic stress response. Unlike pharmaceutical sleep aids such as benzodiazepines or Z-drugs, DSIP does not directly suppress CNS activity. Instead, research suggests it normalizes sleep architecture, making it of interest for studying physiological rather than pharmacological sleep regulation. Compared to melatonin, DSIP operates through fundamentally different mechanisms, targeting delta wave promotion rather than circadian rhythm entrainment. Store lyophilized DSIP at -20°C, protected from light and moisture. Reconstitute with bacteriostatic water and refrigerate at 2-8°C, using within 4 weeks. DSIP is studied by sleep researchers, neuroendocrinologists, and stress physiologists investigating non-pharmacological approaches to sleep architecture restoration.

Pinealon

Pinealon is a synthetic tripeptide with the sequence Glu-Asp-Arg (EDR) that belongs to the Khavinson peptide bioregulator family. It was designed to target pineal gland function, and research suggests it penetrates cell membranes and interacts directly with DNA, modulating gene expression related to neuroprotection and circadian regulation. Its mechanism of action involves upregulation of serotonin synthesis enzymes and modulation of melatonin production pathways in pinealocytes. Research by Khavinson et al. published in Bulletin of Experimental Biology and Medicine demonstrated that Pinealon exhibited neuroprotective effects in cortical neuron cultures exposed to hypoxic and oxidative stress conditions, reducing cell death by up to 40% compared to controls. Additional studies showed that EDR peptide use in aged animal models helped restore circadian melatonin rhythms that had deteriorated with age. Work published in Advances in Gerontology indicated that Pinealon improved memory consolidation and learning capacity in senescence-accelerated mice. Compared to Epithalon (AEDG), another Khavinson bioregulator peptide targeting the pineal gland, Pinealon operates through distinct mechanisms. While Epithalon primarily activates telomerase and elongates telomeres, Pinealon focuses on direct neuroprotective gene regulation and serotonin pathway support. The two are sometimes studied in conjunction for comprehensive pineal gland and aging research. Lyophilized Pinealon should be stored at -20°C. Reconstitute with bacteriostatic water immediately before use and store at 2-8°C for up to 3 weeks. Researchers in gerontology, chronobiology, and neuroprotection are the primary investigators of this peptide, particularly those studying age-related cognitive decline and circadian disruption.

Frequently Asked Questions